Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaust Limited ( (AU:NUZ) ) has issued an update.
Neurizon Therapeutics has opened a pro-rata non-renounceable entitlement offer to raise up to approximately A$17.1 million before costs, giving eligible shareholders the right to subscribe for two new shares for every five held at an offer price of A$0.08 per share, based on a record date of 30 December 2025. The capital raising, which runs from 5 to 21 January 2026 under an ASX-compliant timetable, is expected to bolster the company’s funding base as it advances clinical development of its ALS candidate NUZ-001 and supports its broader ambitions in neurodegenerative disease, with the structure of the offer providing existing investors an opportunity to maintain their ownership position.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is an ASX-listed clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease, with a strategy to accelerate access to effective ALS therapies while exploring wider neurodegenerative indications through international collaborations and clinical programs.
YTD Price Performance: -3.53%
Average Trading Volume: 728,948
Technical Sentiment Signal: Sell
Current Market Cap: A$61.51M
For detailed information about NUZ stock, go to TipRanks’ Stock Analysis page.